A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
← catalyst calendarSponsored by Vertex Pharmaceuticals Incorporated (industry) · VRTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
88actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-09 | actual | When the study began enrolling |
| Primary completion | 2025-02-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-18 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pain
Interventions
- Drug: VX-993
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Day 1 up to Day 16
Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Day 1 up to Day 43
Permalink · VRTX's whole pipeline · Catalyst calendar · Every registered study · What changed